Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by Sinbobon Aug 27, 2012 11:01am
172 Views
Post# 20264109

RE: News......

RE: News......

Last I heard was that Shire is now deliberating it's future potential/arrangements with BTI and has until Sept. 15th to notify BTI of  whatever offer/decision it has arrived at. So, I guess some sort of news will be released before or shortly after that timeline. Abbott should also have some sort of progress on it's present collaboration soon...and it shouldn't take much longer for other (several?) collaboration agreements to begin. TTU must be close to finished on it's second study and we have no way of knowing  how many other large pharmas are making initiatives at this time. (Roche?)

Judging by the very tight lipped atmosphere and the purposefully low key mail out re the AGM tomorrow, it would appear that RH is being extremely conservative and careful during this sensitive time frame. Is it too early for a buy out offer? I would have to think that would be very premature at this time...even if BTI management would entertain such overtures. All this is totally navel gazing on my part and there are many other astute investors here who have pretty well figured it all out. I get the impression that they are so confident in their expections that postiing here is pretty much unnecessary.

Whether there is enough motivation, based on the years of cumulative research and studies, for a major too take  precocious leap of faith here, I leave to others for open debate.

Bullboard Posts